NCT04314089View on ClinicalTrials.gov

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

April 11, 2024

Study Completion Date

December 30, 2024

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

GT103

intravenously (dose depending)

Trial Locations (3)

27540

Duke University Medical Center, Durham

34747

Advent Health, Celebration

48201

Karmanos Cancer Institute, Detroit

All Listed Sponsors

lead

Edward Patz

OTHER

NCT04314089 - Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) | Biotech Hunter | Biotech Hunter